Tirzepatide
A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Shows superior weight loss efficacy vs. semaglutide in trials.
Quick Reference
- Onset
- Days-weeks (cumulative)
- Duration
- Weekly dosing
- Intensity
- Moderate-strong
- Legal status
- Legal (US)
- Evidence level
- Research-backed
Key Compounds
Effects
The Science
Content generated via CMS — mechanism of action, pharmacology, and research summaries will appear here.
Dosage
Content generated via CMS — dosage tiers, timing recommendations, and form-specific guidance will appear here.
Forms & How to Use
Content generated via CMS — available forms (powder, capsule, tincture, etc.) and preparation guidance will appear here.
Safety
Content generated via CMS — contraindications, interactions, and safety profile information will appear here.
Health Disclaimer: This information is for educational purposes only and is not medical advice. Consult a qualified healthcare provider before using any substance, especially if you take medications or have a medical condition.
Legal Status
An interactive legal status map will appear here. Check legality by state and country.
Trusted Vendors
Vendor listings coming soon. We vet every vendor for third-party testing, GMP compliance, and transparent sourcing.
Key Compounds
Sources & Citations
Content generated via CMS — peer-reviewed references, clinical trials, and source links will appear here.